glipizide has been researched along with 2019 Novel Coronavirus Disease in 1 studies
Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.
glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| AlAjmi, MF | 1 |
| Rehman, MT | 1 |
| Hussain, A | 1 |
1 other study available for glipizide and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Celecoxib, Glipizide, Lapatinib, and Sitagliptin as potential suspects of aggravating SARS-CoV-2 (COVID-19) infection: a computational approach.
Topics: Angiotensin-Converting Enzyme 2; Celecoxib; COVID-19; Glipizide; Humans; Lapatinib; Molecular Dockin | 2022 |